Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Long-Term Debt Repayments (2017)

Heron Therapeutics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $25.0 million for Q2 2017.

  • For Q2 2017, Long-Term Debt Repayments changed N/A year-over-year to $25.0 million; the TTM value through Dec 2018 reached $25.0 million, changed N/A, while the annual FY2025 figure was $125.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $25.0 million in Q2 2017 per HRTX's latest filing.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $25.0 million in Q2 2017 to a low of $25.0 million in Q2 2017.